GT Biopharma (GTBP) Non Operating Income (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Non Operating Income of $15000.0 for Q1 2026, down 98.7% year-over-year from $1.2 million in Q1 2025, and up 113.27% quarter-over-quarter from -$113000.0 in Q4 2025.
GT Biopharma (GTBP) Non Operating Income (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Non Operating Income for 17 consecutive years, with $15000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 98.7% year-over-year to $15000.0; the TTM figure through Mar 2026 stood at -$17.1 million (down 1213.7% YoY), while the FY2025 annual figure was -$15.9 million, down 1425.46% from the prior year.
- Non Operating Income rose to $15000.0 in Q1 2026 per GTBP's latest filing, from -$113000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $11.7 million in Q3 2025 and bottomed at -$28.7 million in Q2 2025.
- Historically, Non Operating Income has averaged -$491941.2 across 5 years, with a median of $194000.0 in 2022.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 171800.0% — and 2025, when it sank 14720.41%.
- GT Biopharma's Non Operating Income stood at $194000.0 in 2022, then gained by 6.19% to $206000.0 in 2023, then sank by 105.83% to -$12000.0 in 2024, then sank by 841.67% to -$113000.0 in 2025, then soared by 113.27% to $15000.0 in 2026.
- Business Quant data shows GTBP's Non Operating Income at $15000.0 in Q1 2026, -$113000.0 in Q4 2025, and $11.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | -113,000.00 |
| Sep 30, 2025 | 11.68 Mn |
| Jun 30, 2025 | -28.66 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | -12,000.00 |
| Sep 30, 2024 | 193,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Mar 31, 2024 | 825,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Sep 30, 2023 | 706,000.00 |
| Jun 30, 2023 | 1.63 Mn |
| Mar 31, 2023 | 3.44 Mn |
| Dec 31, 2022 | 194,000.00 |
| Sep 30, 2022 | 142,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 156,000.00 |
| Sep 30, 2021 | 501,000.00 |
| Jun 30, 2021 | -480,000.00 |